Sunifiram Research Overview (also known as DM-235, 1-BCP, piperazine-2-carboxamide)
Sunifiram (DM-235) is a synthetic ampakine-like research compound developed from the piracetam-related nootropic research tradition, although it is structurally distinct from piracetam and has been described in preclinical literature as substantially more potent, with some secondary sources estimating an approximately 1,000-fold difference. Animal and cellular studies suggest modulation of AMPA- and NMDA-receptor-associated signaling, including pathways involving protein kinase C, CaM-KII, acetylcholine, and long-term potentiation; however, the compound remains an early-stage research chemical with no established clinical use, standardized human dose, or adequate human safety data.
What Is Sunifiram?
Sunifiram, also known by the laboratory code DM-235, is a synthetic cognitive research compound associated with the University of Florence pharmacology program and the broader racetam and ampakine research fields. It is often described as an ampakine-like compound because its reported effects are related to excitatory glutamatergic signaling, particularly AMPA-receptor function. The compound has attracted attention in nootropic communities because animal experiments reported effects on learning, memory, and pharmacologically induced amnesia. Those findings should not be confused with evidence of effectiveness in people: there are no robust randomized clinical trials establishing benefit, safety, pharmacokinetics, or an appropriate human dose.
Sunifiram is structurally different from piracetam rather than being a simple chemical form of it. Descriptions commonly emphasize a modified piperazine-containing scaffold and a much higher apparent potency in selected laboratory assays, with an often-repeated estimate of approximately 1,000 times the potency of piracetam. That estimate is not a validated clinical conversion factor and cannot be used to calculate a human dose. Commercial names and chemical descriptions can also be inconsistent; labels such as 1-BCP and piperazine-2-carboxamide should not be treated as reliable identity confirmation without analytical testing. Because the compound is not an approved medicine and has very limited human research, any nonclinical use carries substantial uncertainty.
Research Indications
Preclinical Cognitive Research
Memory-task performance in animals
Sunifiram has been evaluated in rodent learning and memory paradigms, including models involving experimentally induced cognitive impairment. These findings are preclinical and do not establish cognitive benefit in humans.
Amnesia-model research
Animal experiments have examined whether the compound modifies performance deficits associated with cholinergic disruption or other laboratory memory-impairment models.
Glutamatergic Signaling
AMPA-related hypotheses
Sunifiram is commonly described as an ampakine-like research compound. Its precise pharmacology remains incompletely characterized, and it should not be assumed to have the same effects as established AMPA-receptor modulators.
Intracellular signaling studies
Experimental work has implicated glutamatergic and cholinergic signaling pathways, but receptor selectivity, potency, and downstream effects in humans are not well defined.
Mood and Motivation Claims
Subjective mood reports
Reports of altered motivation, mood, or sociability are anecdotal. Controlled clinical studies supporting these effects have not been established.
Potential overstimulation
Because subjective stimulation and anxiety-like effects are also reported, mood-related claims should not be interpreted as evidence of safety or therapeutic utility.
Human Evidence Gap
No established therapeutic indication
Sunifiram is not an approved medicine for cognitive, mood, or neurological conditions. Robust human pharmacokinetic, dose-ranging, and efficacy data are lacking.
Unknown long-term risk profile
Published evidence does not adequately characterize chronic exposure, withdrawal effects, reproductive risks, or interactions with prescription medicines.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Preclinical cognition studies | Animal-model dependent | Study protocol dependent | Oral |
| Human cognitive enhancement | No established human dose | Not established | Oral |
| Mood or motivation effects | No established human dose | Not established | Oral |
| Long-term use | No evidence-based range | Not established | Oral |
Timing
There is no validated human timing, titration, cycling, or washout protocol for sunifiram. Avoid treating anecdotal schedules as clinically established guidance, particularly when combining stimulants or other psychoactive substances.
Peptide Interactions
May add to insomnia, tremor, palpitations, anxiety, or headache. Human interaction data are unavailable.
Combination with amphetamine- or methylphenidate-class medicines may increase stimulant-like adverse effects and should be reviewed by a prescriber.
Avoid unsupervised combination: bupropion can lower seizure threshold, while sunifiram has insufficient safety characterization and possible excitatory activity.
Avoid combining psychoactive substances when pharmacodynamic and impairment effects are unknown; subjective stimulation can mask intoxication.
No adequate interaction studies exist. Changes in sleep, anxiety, agitation, or mood may complicate monitoring of antidepressant treatment.
Despite structural comparisons, combined use lacks controlled safety evidence and may make adverse-effect attribution difficult.
Reported Research Timeline
01First exposure (reported in cited studies): no reliable human onset profile has been established. Anecdotal reports describe variable subjective effects, while others report no noticeable acute change.
02Hours after use (reported in cited studies): possible unwanted effects reported in uncontrolled settings include headache, restlessness, irritability, visual disturbance, nausea, and sleep disruption.
03Days 1–7 (reported in cited studies): there is no controlled evidence that perceived focus, memory, or mood changes are sustained, reproducible, or distinguishable from expectancy effects.
04Weeks 2–4 (reported in cited studies): tolerance, sensitization, mood effects, and cumulative safety have not been adequately studied in humans. Escalating exposure is not evidence-based.
05Months (reported in cited studies): no meaningful clinical data define long-term neuropsychiatric, cardiovascular, hepatic, reproductive, or withdrawal outcomes.
06Any time: stop exposure and seek professional guidance if new neurological, psychiatric, cardiac, or visual symptoms occur.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Sunifiram is not approved as a medicine, and robust human safety, pharmacokinetic, and long-term toxicity data are lacking.
Avoid use during pregnancy or breastfeeding and in children or adolescents because developmental and reproductive risks are unknown.
Avoid use with a seizure history, epilepsy, significant head injury, or medicines that may lower seizure threshold unless specifically cleared by a clinician.
People with bipolar-spectrum illness, psychosis, panic disorder, or severe insomnia may be particularly vulnerable to activating or destabilizing effects.
Do not drive, operate machinery, or make safety-critical decisions if experiencing altered vision, dizziness, agitation, impaired concentration, or sleep deprivation.
Product identity and dose may be unreliable in unregulated markets; contamination, substitution, and labeling error are material risks.
Seek Medical Attention If:
A seizure, loss of consciousness, severe confusion, or unusual involuntary movements occur.
Chest pain, fainting, persistent rapid heartbeat, severe shortness of breath, or marked blood-pressure symptoms develop.
Severe agitation, hallucinations, mania-like behavior, suicidal thoughts, or inability to sleep for a prolonged period occurs.
There is facial swelling, hives, wheezing, severe vomiting, or any suspected serious allergic reaction.
Quality Indicators
Verified Marker
Lot-specific certificate of analysis
Look for a dated, batch-matched COA identifying sunifiram by an appropriate analytical method rather than a generic vendor statement.
Verified Marker
Independent HPLC or LC-MS identity testing
Prefer documentation from an identifiable third-party laboratory showing analyte identity and a stated purity result for the specific lot.
Verified Marker
Contaminant screening
A credible report includes relevant heavy-metal and microbiological testing, especially for oral powders or capsules intended for consumer sale.
Acceptable Range
Capsule mass and label accuracy
For capsules, verify the labeled milligram content, excipients, lot number, and expiration date; capsule-fill weight alone does not confirm active-compound content.
Quality Concern
Unverifiable purity or research-only disclaimer
Avoid products lacking batch-level analytical documentation, using only marketing claims, or presenting “research use only” material as a dietary supplement or medicine.
Research Citations
- Facilitation of glutamate receptors enhances memory
Staubli, U., Rogers, G., Lynch, G., 1994, Proceedings of the National Academy of Sciences of the United States of America - Effects of the potent ampakine CX614 on hippocampal and cortical synaptic transmission and plasticity
Arai, A. C., Kessler, M., Rogers, G., et al., 2000, Journal of Pharmacology and Experimental Therapeutics - AMPA receptor modulators as cognitive enhancers
Lynch, G., 2004, Current Opinion in Pharmacology - AMPA receptor positive allosteric modulators: a therapeutic opportunity?
Arai, A. C., 2005, Neuropharmacology
Research Focus
AMPA modulation, NMDA, LTP, memory, extreme potency, PKC alpha, acetylcholine
Frequently Asked Questions
What should researchers watch for with Sunifiram?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Sunifiram?
First exposure (reported in cited studies): no reliable human onset profile has been established. Anecdotal reports describe variable subjective effects, while others report no noticeable acute change.
How is Sunifiram typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →